Clin Endosc.  2021 Nov;54(6):818-824. 10.5946/ce.2020.296.

The Role of Endoscopy in Small Bowel Neuroendocrine Tumors

• Yoon JY
• Kumta NA
• Kim MK

• KMID: 2522701
• DOI: http://doi.org/10.5946/ce.2020.296

Abstract

Small bowel neuroendocrine tumors (NETs) represent approximately one-third of NETs of the gastrointestinal tract, and their incidence is increasing. When determining if endoscopic resection is appropriate, endoscopic ultrasound is used to assess the lesion size and depth of invasion for duodenal NETs. A number of techniques, including endoscopic mucosal resection (EMR), band-assisted EMR (band-EMR), endoscopic submucosal dissection (ESD), and over-the-scope clip-assisted endoscopic full-thickness resection (EFTR), have been studied; however, the best technique for endoscopic resection remains unclear. The vast majority of currently available data are retrospective, and prospective studies with longer follow-up times are required. For jejunal and ileal NETs, endoscopic techniques such as video capsule endoscopy (VCE) and balloon enteroscopy (BE) assist in diagnosis. This includes localization of the primary NET in metastatic disease where initial workup has been negative, and the identification of multifocal disease, which may change management and prognostication.

Keyword

Neuroendocrine tumors; Carcinoid tumors; Endoscopy; Small intestine

Figure

• 

  Fig. 1. Endoscopic mucosal resection of a duodenal neuroendocrine tumor. (A) A duodenal bulb neuroendocrine tumor. (B) After endoscopic mucosal resection. (C) Closure of mucosal defect using clips.

Reference

1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017; 3:1335–1342.

2. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26:3063–3072.

3. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009; 249:63–71.

4. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011; 40:1–18. vii.

5. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010; 39:753–766.

6. Landerholm K, Falkmer S, Järhult J. Epidemiology of small bowel carcinoids in a defined population. World J Surg. 2010; 34:1500–1505.

7. Dalenbäck J, Havel G. Local endoscopic removal of duodenal carcinoid tumors. Endoscopy. 2004; 36:651–655.

8. Kulke MH, Shah MH, Benson AB, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw JNCCN. 2015; 13:78–108.

9. Burke AP, Sobin LH, Federspiel BH, Shekitka KM, Helwig EB. Carcinoid tumors of the duodenum. A clinicopathologic study of 99 cases. Arch Pathol Lab Med. 1990; 114:700–704.

10. Hatta W, Koike T, Iijima K, et al. The risk factors for metastasis in non-ampullary duodenal neuroendocrine tumors measuring 20 mm or less in diameter. Digestion. 2017; 95:201–209.

11. Zyromski NJ, Kendrick ML, Nagorney DM, et al. Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg Off J Soc Surg Aliment Tract. 2001; 5:588–593.

12. Untch BR, Bonner KP, Roggin KK, et al. Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2014; 18:457–462. discussion 462-463.

13. Vanoli A, La Rosa S, Klersy C, et al. Four neuroendocrine tumor types and neuroendocrine carcinoma of the duodenum: analysis of 203 cases. Neuroendocrinology. 2017; 104:112–125.

14. Park SG, Lee BE, Kim GH, et al. Risk factors for lymph node metastasis in duodenal neuroendocrine tumors: A retrospective, single-center study. Medicine (Baltimore). 2019; 98:e15885.

15. Lee SW, Sung JK, Cho YS, et al. Comparisons of therapeutic outcomes in patients with nonampullary duodenal neuroendocrine tumors (NADNETs): a multicenter retrospective study. Medicine (Baltimore). 2019; 98:e16154.

16. Delle Fave G, O’Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016; 103:119–124.

17. Kumar S, Mahmud N, Roses RE, Katona BW, Ginsberg GG, Metz DC. Resection trends for duodenal carcinoid tumors: a single-center experience. Pancreas. 2020; 49:E11–E13.

18. Kim GH, Kim JI, Jeon SW, et al. Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study. J Gastroenterol Hepatol. 2014; 29:318–324.

19. Park SB, Kang DH, Choi CW, Kim HW, Kim SJ. Clinical outcomes of ligation-assisted endoscopic resection for duodenal neuroendocrine tumors. Medicine (Baltimore). 2018; 97:e0533.

20. Fujimoto A, Sasaki M, Goto O, et al. Treatment results of endoscopic mucosal resection with a ligation device for duodenal neuroendocrine tumors. Intern Med Tokyo Jpn. 2019; 58:773–777.

21. Osera S, Oono Y, Ikematsu H, Yano T, Kaneko K. Endoscopic submucosal resection with a ligation device for the treatment of duodenal neuroendocrine tumors. Surg Endosc. 2016; 30:3928–3932.

22. Oono Y, Shinmura K, Hori K, et al. Endoscopic submucosal resection using a ligation device without injection for duodenal neuroendocrine tumors. Surg Endosc. 2019; 33:2008–2014.

23. Matsumoto S, Miyatani H, Yoshida Y. Endoscopic submucosal dissection for duodenal tumors: a single-center experience. Endoscopy. 2013; 45:136–137.

24. Nishio M, Hirasawa K, Ozeki Y, et al. Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors. Ann Gastroenterol. 2020; 33:265–271.

25. Kim SH, Park CH, Ki HS, et al. Endoscopic treatment of duodenal neuroendocrine tumors. Clin Endosc. 2013; 46:656–661.

26. Li Q-L, Zhang Y-Q, Chen W-F, et al. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol. 2012; 18:5799–5806.

27. Matsumoto S, Miyatani H, Yoshida Y, Nokubi M. Duodenal carcinoid tumors: 5 cases treated by endoscopic submucosal dissection. Gastrointest Endosc. 2011; 74:1152–1156.

28. Al-Bawardy B, Rajan E, Wong Kee Song LM. Over-the-scope clip-assisted endoscopic full-thickness resection of epithelial and subepithelial GI lesions. Gastrointest Endosc. 2017; 85:1087–1092.

29. Sarker S, Gutierrez JP, Council L, Brazelton JD, Kyanam Kabir Baig KR, Mönkemüller K. Over-the-scope clip-assisted method for resection of full-thickness submucosal lesions of the gastrointestinal tract. Endoscopy. 2014; 46:758–761.

30. Kappelle WFW, Backes Y, Valk GD, Moons LMG, Vleggaar FP. Endoscopic full-thickness resection of gastric and duodenal subepithelial lesions using a new, flat-based over-the-scope clip. Surg Endosc. 2018; 32:2839–2846.

31. Hajifathalian K, Ichkhanian Y, Dawod Q, et al. Full-thickness resection device (FTRD) for treatment of upper gastrointestinal tract lesions: the first international experience. Endosc Int Open. 2020; 8:E1291–E1301.

32. Niederle B, Pape U-F, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016; 103:125–138.

33. Yantiss RK, Odze RD, Farraye FA, Rosenberg AE. Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. Am J Surg Pathol. 2003; 27:811–817.

34. Koopmans KP, de Vries EGE, Kema IP, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006; 7:728–734.

35. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013; 20:285–314.

36. Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg Chic Ill 1960. 2010; 145:276–280.

37. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009; 16:885–894.

38. Rondonotti E, Pennazio M, Toth E, et al. Small-bowel neoplasms in patients undergoing video capsule endoscopy: a multicenter European study. Endoscopy. 2008; 40:488–495.

39. Cobrin GM, Pittman RH, Lewis BS. Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer. 2006; 107:22–27.

40. Bailey AA, Debinski HS, Appleyard MN, et al. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol. 2006; 101:2237–2243.

41. Lewis BS, Eisen GM, Friedman S. A pooled analysis to evaluate results of capsule endoscopy trials. Endoscopy. 2005; 37:960–965.

42. Furnari M, Buda A, Delconte G, et al. The role of wireless capsule endoscopy (WCE) in the detection of occult primary neuroendocrine tumors. J Gastrointest Liver Dis JGLD. 2017; 26:151–156.

43. Girelli CM, Porta P, Colombo E, Lesinigo E, Bernasconi G. Development of a novel index to discriminate bulge from mass on small-bowel capsule endoscopy. Gastrointest Endosc. 2011; 74:1067–1074. quiz 1115.e1-e5.

44. Yamamoto H, Kita H, Sunada K, et al. Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal diseases. Clin Gastroenterol Hepatol. 2004; 2:1010–1016.

45. Imaoka H, Higaki N, Kumagi T, et al. Characteristics of small bowel tumors detected by double balloon endoscopy. Dig Dis Sci. 2011; 56:2366–2371.

46. Partridge BJ, Tokar JL, Haluszka O, Heller SJ. Small bowel cancers diagnosed by device-assisted enteroscopy at a U.S. referral center: a five-year experience. Dig Dis Sci. 2011; 56:2701–2705.

47. Mitsui K, Tanaka S, Yamamoto H, et al. Role of double-balloon endoscopy in the diagnosis of small-bowel tumors: the first Japanese multicenter study. Gastrointest Endosc. 2009; 70:498–504.

48. Cangemi DJ, Patel MK, Gomez V, Cangemi JR, Stark ME, Lukens FJ. Small bowel tumors discovered during double-balloon enteroscopy: analysis of a large prospectively collected single-center database. J Clin Gastroenterol. 2013; 47:769–772.

49. Bellutti M, Fry LC, Schmitt J, et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci. 2009; 54:1050–1058.

50. Manguso N, Gangi A, Johnson J, et al. The role of pre-operative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary? J Surg Oncol. 2018; 117:207–212.

51. Gangi A, Siegel E, Barmparas G, et al. Multifocality in small bowel neuroendocrine tumors. J Gastrointest Surg. 2018; 22:303–309.

52. Ethun CG, Postlewait LM, Baptiste GG, et al. Small bowel neuroendocrine tumors: a critical analysis of diagnostic work-up and operative approach. J Surg Oncol. 2016; 114:671–676.

53. Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: Consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017; 46:715–731.